US Administration takes new steps to fight Alzheimer's disease

8 February 2012

In the USA, the Obama Administration this week announced new efforts to fight Alzheimer’s disease, including immediately making an additional $50 million available for cutting-edge Alzheimer’s research. In addition, the Administration announced that its Fiscal Year 2013 budget will boost funding for Alzheimer’s research by $80 million. This latest announcement also includes an additional $26 million in caregiver support, provider education, public awareness and improvements in data infrastructure.

In January 2011, President Obama signed the National Alzheimer’s Project Act, which calls for an aggressive and coordinated national Alzheimer’s disease plan. The Act also establishes an Advisory Council on Alzheimer’s Research, Care, and Services, which brings together some of the Nation’s foremost experts on Alzheimer’s disease to inform the development of the national plan. The preliminary framework for the National Alzheimer’s Disease Plan identifies key goals including preventing and treating Alzheimer’s by 2025.

“Today’s announcement reflects this administration’s commitment to confronting Health and Human Service (HHS) Secretary Kathleen Sebelius, adding: “We can’t wait to act; reducing the burden of Alzheimer’s disease on patients and their families is an urgent national priority.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical